2016-08-12T17:14:40-05:00 2015-09-30 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE SUITE 1700 IRVINE CA 92612 990 2014-10-01 953432210 Beckman Research Institute of the City of Hope % CORNELIS VAN DEN BERG BECK 6262564673 1450 East Duarte Road Duarte CA 91010 CORNELIS VAN DEN BERG CFO & TREASURER 6262564673 2016-08-04 true KARA ADAMS P00023315 9497942300 2014 2016-09-27 15:27:22Z ROBERT STONE 1500 EAST DUARTE ROAD DUARTE CA 91010 470064671 false X www.cityofhope.org X 1979 CA TO QUICKLY TURN RESEARCH IDEAS INTO NEW TREATMENTS AND CURES THROUGH MEDICAL AND BIOMEDICAL RESEARCH AND DISEASE INVESTIGATION, INCLUDING DNA SYNTHESIS AND CELL ANALYSIS. 7 5 916 0 -159308 247879165 279811394 3828641 6190332 46639302 42151167 591610 2723466 298938718 330876359 0 0 0 0 104459913 108818371 0 0 3039494 160814495 178181339 265274408 286999710 33664310 43876649 1002567058 991819363 145246924 150248331 857320134 841571032 X THE SPECIFIC AND PRIMARY PURPOSE IS TO ENGAGE DIRECTLY IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH. SEE SCHEDULE O. false false 246042561 6201972 BIOMEDICAL RESEARCH AND DISEASE INVESTIGATIONS, INCLUDING DNA SYNTHESIS AND CELL ANALYSIS. BECKMAN RESEARCH INSTITUTE HAS PIONEERED SCIENTIFIC BREAKTHROUGHS RESULTING IN TREATMENTS THAT HAVE IMPROVED THE LIVES OF PATIENTS WORLDWIDE. NUMEROUS LIFE-SAVING DRUGS USE PATENTED TECHNOLOGY DEVELOPED AT BECKMAN RESEARCH INSTITUTE; THESE DRUGS INCLUDE SYNTHETIC HUMAN INSULIN (HUMULIN) FOR DIABETES, THE WIDELY USED CANCER DRUGS HERCEPTIN, RITUXAN AND AVASTIN, AND HUMIRA FOR ARTHRITIS. SEE SCHEDULE O. 246042561 true true false false false false false false false true true true false false true true false true false false true false false false false false false false false true true false false false false false true false false true false false false false false false true true true false false true X 325 0 true 916 true true true true BD CJ false false false false false false false false X 7 5 false false false false true true true true true false false false true true true true true true true false CA X CORNELIS VAN DEN BERG 6262564673 1500 EAST DUARTE ROAD DUARTE CA 91010 X John Rossi Board Member/Research Sci 60.0 0.0 X 331932 0 63193 Linda Malkas Board Member/Professor 60.0 0.0 X 372159 0 48555 IRIS ROTHSTEIN BOARD MEMBER 3.0 2.0 X 0 0 0 ERNIE SO BOARD CHAIR 3.0 2.0 X 0 0 0 GARY E FREEDMAN BOARD MEMBER 3.0 0.0 X 0 0 0 BENHAM BADIE MD BOARD MEMBER 3.0 0.0 X 0 0 0 ART NEMIROFF BOARD MEMBER 3.0 0.0 X 0 0 0 Boriana Farias Assistant Treasurer - Incoming 15.0 45.0 X 67725 203176 41925 Gregory Schetina Secretary/General Counsel 15.0 45.0 X 143924 431774 150692 William Sargeant Asst Secretary/COO 15.0 45.0 X 220855 662564 219775 Richard Magnuson TREASURER/CFO 15.0 45.0 X 195864 587592 197040 Robert W Stone President and CEO 15.0 45.0 X 348431 1045291 371303 Wael Fakhry Assistant Treasurer - Outgoing 13.0 47.0 X 92952 347580 60586 David Horne Chairperson/Professor 60.0 0.0 X 651786 0 48949 Ashley Baker Lee SVP Rsch Ops 60.0 0.0 X 469154 0 58681 Larry Couture SVP CATD 60.0 0.0 X 466703 0 34474 Debra Fields Chief Risk Officer 15.0 45.0 X 155762 467287 141326 Paul Conocenti SVP and CIO 9.0 51.0 X 93016 527089 73320 Stephanie Neuvirth Chief HR Officer 15.0 45.0 X 224901 674704 155092 Steven Rosen Provost, Cancer Center Dir 34.0 26.0 X 802969 605748 153153 Lisa Stockmon SVP Communications 15.0 45.0 X 61050 183148 1432 Michael Friedman Emeritus Cancer Ctr Director 6.0 54.0 X 98950 890543 53120 Hua Yu Professor 60.0 0.0 X 417442 0 49000 Leslie Bernstein Dean of Faculty Affairs 60.0 0.0 X 404604 0 50997 Rama Natarajan Chairperson/Professor 60.0 0.0 X 307781 0 52450 Jodi Burke Interim Chief HR Officer 15.0 45.0 X 111029 333087 42812 Valerie Bingham Former Officer 15.0 45.0 X 77058 231172 48077 6116047 7190755 2115952 142 true true false WINTERS SCHRAM ASSOCIATES 11777 MISSISSIPPI AVENUE LOS ANGELES CA 90025 GENERAL CONTRACTOR 2449680 PAUL WEISS RIFKIND WHARTON GAR 1285 AVENUE OF THE AMERICAS NEW YORK NY 10019 LEGAL SERVICES 1454618 UNIVERSITY OF SOUTHERN CALIFORINA FILE NO 52095 LOS ANGELES CA 94538 RESEARCH SERVICES 963077 CARL ZEISS MICROSCOPY LLC ONE ZEISS DRIVE THORNWOOD NY 10594 REPAIRS/MAINTENANCE 948229 HURON CONSULTING SERVICES LLC PO BOX 71223 CHICAGO IL 90694 CONSULTING SERVICES 939734 42 223369215 52305850 4136329 20349 279811394 OTHER RESEARCH ACTIVITIES 541990 5502986 5502986 ACADEMIC STAFF REVENUE 541900 115452 115452 SPECIALIZED LAB REVENUE 541900 463844 463844 RENTAL INCOME - PROGRAM SERVICE 541900 108050 108050 6190332 14245377 14245377 0 2871134 2871134 0 0 0 167094102 139188312 27905790 27905790 27905790 0 0 0 INVESTMENT INCOME FROM K-1'S 525990 -159308 -159308 MISCELLANEOUS REVENUE 900004 11640 11640 -147668 330876359 6201972 -159308 45022301 0 0 0 0 4559380 913061 3516669 129650 86376 86376 84318438 71156462 11617813 1544163 5580211 4858716 613823 107672 8828351 7441591 1218459 168301 5445615 4406268 937367 101980 0 5047612 4834070 213542 316242 316242 0 0 2239261 2239261 20484320 13054987 6459621 969712 178328 178328 24489662 21250788 3235563 3311 3809994 783844 3025988 162 0 6182361 5656718 519170 6473 1561845 1272280 289565 0 438931 243016 195915 4883648 4084424 799224 0 15110084 14235611 867111 7362 528016 506094 21226 696 ROYALTY REVENUE SHARING 89773724 89773724 DUES AND SUBSCRIPTIONS 1458796 1140592 318204 TAXES AND LICENSES 247947 9447 238488 12 OTHER MISCELLANEOUS 1430568 420868 1009700 286999710 246042561 37917655 3039494 13316715 15820813 3555212 2834168 10896333 9503143 0 0 460610 448161 0 0 1601765 1403464 194 0 7052 2989220 367183975 143764589 229755772 223419386 305412199 311001813 436031488 423487255 0 0 0 0 1529718 911940 1002567058 991819363 22169904 17844686 0 0 5660409 9647766 55054287 54562287 0 0 0 0 50000000 50000000 0 0 12362324 18193592 145246924 150248331 X 838791089 823478933 4766594 4289299 13762451 13802800 857320134 841571032 1002567058 991819363 X 43876649 -57444437 -2181314 X X false true X true true true X CITY OF HOPE NATIONAL MEDICAL CENTER DUARTE CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 576279312 40694 -13645494 0 530691 0 562143821 514729850 20552 61593960 0 65050 0 576279312 455249503 20000 59716262 0 255945 0 514729820 393755522 25000 61930306 0 461325 0 455249503 405464661 0 -11243318 0 465791 0 393755552 0.96782 0.02455 0.00763 false false 2592400 9695656 12288056 238768954 76009871 162759083 8572 8572 0 104638471 67746146 36892325 11479922 11479922 223419386 ALTERNATIVE INVESTMENTS 423487255 F 423487255 0 DUE TO AFFILIATES 8910201 INTEREST RATE SWAP LIABILITY 5529746 BOND ISSUANCE PREMIUM 2382825 WORKERS COMPENSATION LIABILITY 1370820 18193592 X SCHEDULE D, PART V, LINE 4 ENDOWMENT FUNDS: BECKMAN RESEARCH INSTITUTE HAS BOARD DESIGNATED OR QUASI-ENDOWMENT FUNDS AND OTHER PERMANENT ENDOWMENT FUNDS THAT ARE AVAILABLE TO FUND FUTURE RESEARCH, AND CAPITAL AND EXPANSION NEEDS AS DETERMINED BY THE MANAGEMENT AND THE BOARD OF DIRECTORS. SCHEDULE D, PART X, LINE 2 FASB ASC 740 DISCLOSURE: THE FOLLOWING PARAGRAPH IS FROM THE CONSOLIDATED CITY OF HOPE AND AFFILIATES (CITY OF HOPE, CITY OF HOPE AUXILIARIES, THE MEDICAL CENTER, THE MEDICAL FOUNDATION AND THE BECKMAN RESEARCH INSTITUTE) AUDITED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2015. FINANCIAL ACCOUNTING STANDARDS BOARD (FASB), ACCOUNTING STANDARDS CODIFICATION ASC 740, INCOME TAXES, CLARIFIES THE ACCOUNTING FOR INCOME TAXES BY PRESCRIBING A MINIMUM RECOGNITION THRESHOLD THAT A TAX POSITION IS REQUIRED TO MEET BEFORE BEING RECOGNIZED IN THE FINANCIAL STATEMENTS. FASB ASC 740 ALSO PROVIDES GUIDANCE ON DERECOGNITION, MEASUREMENT, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE GUIDANCE CONTAINED IN FASB ASC 740 IS APPLICABLE TO PASS-THROUGH ENTITIES AND TAX-EXEMPT ORGANIZATIONS. CITY OF HOPE HAS NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITIES FOR TAX BENEFITS, INTEREST OR PENALTIES ACCRUED AT SEPTEMBER 30, 2015 AND 2014. Central America and the Caribbean Investments 109399380 Central America and the Caribbean 4 Program Services Research Symposiums 3948 East Asia and the Pacific 32 Program Services Research Symposiums 85350 Europe (Including Iceland and Greenland) 40 Program Services Research Symposiums 90530 North America 25 Program Services Research Symposiums 33295 South America 6 Program Services Research Symposiums 7861 Sub-Saharan Africa 8 Program Services Research Symposiums 9535 98 115 109629899 109629899 true false true true true false SCHEDULE F, PART I, LINE 3 ACTIVITIES PER REGION: INVESTMENT ACTIVITIES OF THE BECKMAN RESEARCH INSTITUTE INCLUDE INVESTMENTS IN MULTIPLE VEHICLES THAT PROVIDE INVESTMENT INCOME AND RETURNS TO FURTHER THE INSTITUTION'S MISSION AND PROGRAMS. AS A RESULT, THERE ARE INVESTMENTS HELD IN OFFSHORE HEDGE FUNDS, MAINLY REGISTERED AS CAYMAN EXEMPTED CORPORATIONS. THESE INVESTMENTS HELP MITIGATE RISK IN THE PORTFOLIO AND REPRESENT APPROXIMATELY 14.5% OF BECKMAN RESEARCH INSTITUTE'S OVERALL CASH AND INVESTMENT PORTFOLIO. THE BECKMAN RESEARCH INSTITUTE HAS HOLDINGS THAT INCLUDE EQUITY COMINGLED FUNDS THAT INVEST PRIMARILY IN MARKETABLE EQUITY SECURITIES. THESE FUNDS ARE SUBJECT TO CERTAIN NOTICE REQUIREMENTS, BUT CAN BE LIQUIDATED AT LEAST MONTHLY. ALTERNATIVE INVESTMENTS ALSO INCLUDE HEDGE FUNDS AND LIMITED PARTNERSHIP FUNDS INVESTED IN REAL ESTATE AND NATURAL RESOURCES, MASTER LIMITED PARTNERSHIPS, PRIVATE EQUITY AND PRIVATE REAL ASSET FUNDS. ALL OF THESE INVESTMENTS HAVE BEEN INCLUDED IN FORM 990, PART X, LINE 12. RESEARCH SYMPOSIA CONSIST OF SCIENTIFIC MEETINGS THAT BECKMAN RESEARCH INSTITUTE PRINCIPAL INVESTIGATORS AND OTHER RESEARCH STAFF ATTEND FOR EDUCATIONAL, RESEARCH AND SCIENTIFIC PURPOSES AND TO PRESENT AND SHARE RESEARCH OBJECTIVES AND RESULTS. RESEARCH HAS A GLOBAL REACH AND RESEARCH SYMPOSIA ARE OFTEN CONDUCTED IN THE VARIOUS REGIONS IDENTIFIED IN SCHEDULE F. CITY OF HOPE SUPPORTS ATTENDANCE OF OUR RESEARCH STAFF AT THESE SYMPOSIA. EMPLOYEE TRAVELERS MAY MAKE MULTIPLE TRIPS TO THE SAME REGION OR TO MULTIPLE REGIONS DURING A FISCAL YEAR. IN THE CASE WHERE THE SAME EMPLOYEE TRAVELER MADE MORE THAN ONE TRIP TO THE SAME REGION, THEY ARE ONLY COUNTED ONE TIME AS A TRAVELER TO THAT REGION. IF THE SAME EMPLOYEE TRAVELER TRAVELS TO MORE THAN ONE REGION, THAT INDIVIDUAL IS COUNTED ONLY ONCE IN EACH REGION VISITED. THE TOTAL TRAVELERS ON LINE 3A, HOWEVER, ONLY COUNTS THE SAME TRAVELER ONCE IN THE GRAND TOTAL. AS A RESULT THE TOTAL TRAVELERS PER REGION WILL NOT ADD UP TO THE TOTAL ON LINE 3A. WE HAD 12 INSTANCES IN WHICH THE SAME TRAVELER TRAVELED TO MULTIPLE REGIONS DURING THE FISCAL YEAR ENDING SEPTEMBER 30, 2015. THE BECKMAN RESEARCH INSTITUTE DOES NOT HAVE ANY PHYSICAL PRESENCE OR EMPLOYEES OUTSIDE OF THE UNITED STATES. HOWEVER, IT'S REPUTATION AS A WORLD CLASS FACILITY IS INTERNATIONALLY RECOGNIZED. AS A RESULT OF THIS RECOGNITION, THE BECKMAN RESEARCH INSTITUTE RECEIVES DONATIONS AND GRANTS FROM PERSONS AND CORPORATIONS OUTSIDE OF THE UNITED STATES. SCHEDULE F, PART I, COLUMN F THE EXPENDITURES IN COLUMN F ARE DETERMINED USING THE ACCRUAL METHOD OF ACCOUNTING. false true false false false false false true false John Rossi Board Member/Research Sci 308315 0 19594 0 4023 0 38250 0 24943 0 395125 0 0 0 Linda Malkas Board Member/Professor 348539 0 21244 0 2376 0 38250 0 10305 0 420714 0 0 0 David Horne Chairperson/Professor 396389 0 231134 0 24263 0 21320 0 27629 0 700735 0 0 0 Boriana Farias Assistant Treasurer - Incoming 52455 157364 15042 45127 228 685 5428 16284 5053 15160 78206 234620 0 0 Gregory Schetina Secretary/General Counsel 91880 275641 46523 139569 5521 16564 29785 89355 7888 23664 181597 544793 0 0 William Sargeant Asst Secretary/COO 142379 427138 77130 231390 1346 4036 49143 147427 5801 17404 275799 827395 0 0 Michael Friedman Emeritus Cancer Ctr Director 87573 788152 0 0 11377 102391 2132 19188 3180 28620 104262 938351 0 0 Richard Magnuson TREASURER/CFO 130063 390189 63400 190199 2401 7204 46001 138002 3259 9778 245124 735372 0 0 Robert W Stone President and CEO 198133 594399 138750 416250 11548 34642 84313 252939 8513 25538 441257 1323768 0 0 Wael Fakhry Assistant Treasurer - Outgoing 66202 247553 26023 97309 727 2718 6026 22533 6758 25269 105736 395382 0 0 Ashley Baker Lee SVP Rsch Ops 330559 0 134993 0 3602 0 28452 0 30229 0 527835 0 0 0 Larry Couture SVP CATD 334289 0 116422 0 15992 0 21320 0 13154 0 501177 0 0 0 Debra Fields Chief Risk Officer 91601 274803 59967 179901 4194 12583 27695 83086 7636 22909 191093 573282 0 0 Paul Conocenti SVP and CIO 60070 340395 31053 175968 1893 10726 5850 33150 5148 29172 104014 589411 0 0 Stephanie Neuvirth Chief HR Officer 115827 347482 66204 198611 42870 128611 30253 90757 8521 25561 263675 791022 25607 76819 Steven Rosen Provost, Cancer Center Dir 334786 252558 427500 322500 40683 30690 73770 55651 13527 10205 890266 671604 0 0 Lisa Stockmon SVP Communications 14388 43163 37500 112500 9162 27485 0 0 358 1074 61408 184222 0 0 Hua Yu Professor 273539 0 142742 0 1161 0 39000 0 10000 0 466442 0 0 0 Leslie Bernstein Dean of Faculty Affairs 341040 0 60524 0 3040 0 38250 0 12747 0 455601 0 0 0 Rama Natarajan Chairperson/Professor 285465 0 20457 0 1859 0 39000 0 13450 0 360231 0 0 0 Valerie Bingham Former Officer 58929 176788 16023 48067 2106 6317 4905 14714 7115 21343 89078 267229 0 0 Jodi Burke Interim Chief HR Officer 73322 219964 17997 53992 19710 59131 2015 6045 8688 26064 121732 365196 0 0 SCHEDULE J, PART I, LINE 3 THE CHIEF EXECUTIVE OFFICER OF THE ORGANIZATION IS NOT COMPENSATED BY THE BECKMAN RESEARCH INSTITUTE BUT BY THE MEDICAL CENTER. CHIEF EXECUTIVE OFFICER COMPENSATION IS ESTABLISHED BY THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE CITY OF HOPE BOARD OF DIRECTORS. ALL SOURCES INDICATED IN LINE 3 ARE UTILIZED BY THIS COMMITTEE TO SET SUCH COMPENSATION. SEE NARRATIVE FOR SCHEDULE O, PART VI, LINE 15A AND PART VII, COLUMN B. SCHEDULE J, PART I, LINE 4B THE BECKMAN RESEARCH INSTITUTE HAS AN EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS A NON-QUALIFIED SECTION 457(F) PLAN. THE PLAN IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICE AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN B(III). PRIOR TO VESTING THE ANNUAL AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN C. PURSUANT TO THE PLAN DOCUMENT, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL, AND FICA TAXES. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. DURING CALENDAR YEAR 2014 THE FOLLOWING INDIVIDUALS WITHDREW THE REFERENCED AMOUNTS TO COVER SUCH TAXES: VALERIE BINGHAM $ 1,244 LARRY COUTURE $ 3,163 MICHAEL FRIEDMAN $19,757 DAVID HORNE $ 5,493 GREGORY SCHETINA $ 4,953 ROBERT STONE $14,490 DEBRA FIELDS $ 4,339 STEPHANIE NEUVIRTH $56,490 JODIE BURKE $26,053 THESE AMOUNTS HAVE BEEN INCLUDED IN THE PARTICIPANTS' INCOME ON SCHEDULE J, PART II, COLUMN B(III). SCHEDULE J, PART I, LINE 7 THE BECKMAN RESEARCH INSTITUTE EXECUTIVES AND SOME KEY EMPLOYEES ARE ELIGIBLE TO RECEIVE INCENTIVE COMPENSATION TIED TO TWO (2) KEY INDICATORS AND TWO OR MORE INDIVIDUAL OBJECTIVES. THE KEY INDICATORS REFLECT KEY AREAS OF STRATEGIC FOCUS AND THE EXEMPT HEALTHCARE MISSION OF THE CITY OF HOPE AND AFFILIATES AND ARE BOTH FINANCIAL AND NON-FINANCIAL. THE POTENTIAL INCENTIVE COMPENSATION IS BASED ON A WEIGHTED AVERAGE AMONG ALL INDICATORS AND IS PAID AS A PERCENTAGE OF EACH INDIVIDUAL PARTICIPANT'S BASE COMPENSATION. THE KEY INDICATORS ARE WEIGHTED AT 30%, WHILE THE INDIVIDUAL OBJECTIVES ARE WEIGHTED AT 70%. BASED UPON AN INDIVIDUAL'S GOALS AND PERFORMANCE DURING THE YEAR, THE POTENTIAL PAYOUT FOR ANY PARTICIPANT CAN BE MODIFIED UP OR DOWN BY AS MUCH AS 20% UPON THE RECOMMENDATION OF THE PRESIDENT AND CHIEF EXECUTIVE OFFICER AND WITH THE CONCURRENCE OF THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE. THE INCENTIVE PLAN IS UNDER THE CONTROL OF AND ADMINISTERED BY THE INDEPENDENT DIRECTORS SERVING ON THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE. CITY OF HOPE MAY IN ITS DISCRETION CANCEL ALL OR A PORTION OF ANY INCENTIVE PLAN PAYMENT OR AWARD TO ANY PARTICIPANT, WHETHER BEFORE OR FOLLOWING PAYMENT OF SUCH AWARD, SUBJECT TO COMPLIANCE WITH APPLICABLE LAW, UNDER THESE CIRCUMSTANCES: A) AN INCENTIVE PLAN PAYMENT OR AWARD IS MADE FOR A FISCAL PERIOD AND CITY OF HOPE SUBSEQUENTLY RESTATES OR OTHERWISE ADJUSTS THE ANNUAL PERFORMANCE MEASUREMENT CALCULATION IN A MANNER THAT WOULD REDUCE THE SIZE OF THE AWARD OR PAYMENT, OR; B) AN INCENTIVE PLAN PAYMENT OR AWARD IS MADE FOR A FISCAL PERIOD AND CITY OF HOPE SUBSEQUENTLY DETERMINES THAT ONE OR MORE OF THE ANNUAL PERFORMANCE MEASUREMENT CALCULATIONS ON WHICH THE AWARD IS BASED ON OR IS PAID ARE MATERIALLY INACCURATE. DURING CALENDAR YEAR 2014 CITY OF HOPE PAID THE INCENTIVE COMPENSATION EARNED FOR FISCAL YEAR 2014 AND THIS HAS BEEN REPORTED IN SCHEDULE J, PART II, COLUMN B(II). THE BECKMAN RESEARCH INSTITUTE HAS AN EXECUTIVE LONG TERM INCENTIVE PLAN (LTI) THAT IS DESIGNED TO PROVIDE A LONG TERM INCENTIVE FOR EXECUTIVES OF THE CITY OF HOPE AND AFFILIATES. IN ORDER TO ACCOMPLISH AND REALIZE KEY ORGANIZATIONAL OBJECTIVES AND GOALS OVER THE NEXT TEN YEAR PERIOD, IT IS CRITICAL THAT KEY EXECUTIVES BE ALIGNED WITH THE STRATEGIC PLAN. THE INITIAL PERFORMANCE PERIOD OF THE PLAN (CYCLE 1) RUNS FROM OCTOBER 1, 2012 THROUGH SEPTEMBER 30, 2015, WITH A NEW THREE YEAR PERFORMANCE PERIOD BEGINNING EACH OCTOBER 1 THEREAFTER (E.G., CYCLE 2 RUNS FROM OCTOBER 1, 2013 THROUGH SEPTEMBER 30, 2016). THE PARTICIPANTS MUST BE EMPLOYED BY THE BECKMAN RESEARCH INSTITUTE AT THE END OF THE PERFORMANCE PERIOD IN ORDER TO VEST IN THE PLAN. WHILE THE LTI DOES MEET THE REQUIREMENTS FOR A SUBSTANTIAL RISK OF FORFEITURE, AS OF THE CALENDAR YEAR ENDING DECEMBER 30, 2014, 9 MONTHS OF YEAR TWO PLAN CYCLE 1, 3 MONTHS OF YEAR THREE PLAN CYCLE 1, 9 MONTHS OF YEAR ONE PLAN CYCLE 2, 3 MONTHS OF YEAR TWO PLAN CYCLE 2, AND 3 MONTHS OF YEAR ONE PLAN CYCLE 3, OF THE POTENTIAL LTI AMOUNTS HAVE BEEN ESTIMATED AND ACCRUED DURING THE CURRENT TAX YEAR AND IS REPORTED AS DEFERRED COMPENSATION TO THE PLAN PARTICIPANTS IN SCHEDULE J, PART II, COLUMN C. SCHEDULE J, PART II JOHN J. ROSSI, PHD, AND LINDA MALKAS, PHD, ARE MEMBERS OF THE BOARD OF DIRECTORS OF THE BECKMAN RESEARCH INSTITUTE AND ARE ALSO EMPLOYEES OF AND COMPENSATED BY THE BECKMAN RESEARCH INSTITUTE. DR. ROSSI IS A RESEARCH SCIENTIST AND DIRECTOR OF MOLECULAR MEDICINE AND THE DEAN OF THE CITY OF HOPE'S IRELL AND MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. DR. MALKAS IS A PROFESSOR AND DEPUTY DIRECTOR FOR BASIC RESEARCH FOR THE CANCER CENTER. NEITHER DR. ROSSI NOR DR. MALKAS ARE COMPENSATED FOR THEIR SERVICES AS A MEMBER OF THE BECKMAN RESEARCH INSTITUTE'S BOARD OF DIRECTORS. EMPLOYEE COMPENSATION FOR BOTH OF THESE INDIVIDUALS IS LISTED ON SCHEDULE J, PART II AND FORM 990, PART VII, SECTION A. A CALIF HLTH FACLTY FIN AUTH (SEE PART VI) 521643828 13033LN37 2012-11-14 57928340 REFUNDING ISSUE/CAPITAL PROJECTS false false false A 0 0 57928742 0 0 0 534551 0 0 9853233 47540958 0 2014 true false true true A false true true true true true 0.01160 0.00040 0.01200 false false false true A false true true true UNION BKWELLS FARGO 30. false false false 0 false true A true SCHEDULE K, PART I, LINE A AN ELECTION WAS MADE UNDER 1.150-1(C)(3) TO TREAT THE BOND ISSUE AS TWO SEPARATE ISSUES AND WAS REPORTED ON TWO SEPARATE FORMS 8038. ONE WAS FOR REFUNDING THE CITY OF HOPE NATIONAL MEDICAL CENTER'S CITY OF DUARTE CERTIFICATES OF PARTICIPATION SERIES 1999A AND THE OTHER WAS FOR REFUNDING (1) THE CITY OF HOPE NATIONAL MEDICAL CENTER PROJECT SERIES 2006A,B,C ISSUES AND (2) THE BECKMAN RESEARCH INSTITUTE'S 2007 CALIFORNIA ENTERPRISE DEVELOPMENT AUTHORITY ISSUE. THIS SECOND FORM 8038 REPORTED AN ISSUE PRICE OF $198,734,018. FOR PURPOSES OF SCHEDULE K REPORTING, THE BECKMAN RESEARCH INSTITUTE IS REPORTING AN ALLOCABLE AMOUNT OF THE ISSUE PRICE AND EXPENDITURES. BECKMAN RESEARCH INSTITUTE IS REPORTING AN ISSUE PRICE OF $57,928,340, WHILE THE CITY OF HOPE NATIONAL MEDICAL CENTER IS REPORTING AN ISSUE PRICE OF $140,805,678. SCHEDULE K, PART I, LINE A COLUMN (F) THE 2012 ISSUE REFUNDED THE FOLLOWING BECKMAN RESEARCH INSTITUTE TAX EXEMPT ISSUE: PRIVATE PLACEMENT ISSUED ON JULY 12, 2007 THROUGH CALIFORNIA ENTERPRISE DEVELOPMENT AUTHORITY. SCHEDULE K, PART II, LINE 11, COLUMN A THE OTHER SPENT PROCEEDS ARE THE REFUNDING PROCEEDS OF THE ISSUE WHICH ARE NO LONGER IN ESCROW. SCHEDULE K, PART IV CITY OF HOPE COMPLETED THE REBATE COMPUTATION ON SEPTEMBER 3, 2015 WITH NO REBATE LIABILITY DUE. Linda Malkas DIRECTOR Mtg Subsidy X 500000 448161 false true true 448161 KIRSTEN ROOD SPOUSE OF A KEY EMPLOYEE 134418 EMPLOYEE COMPENSATION false SYLVANA COUTURE SPOUSE OF A KEY EMPLOYEE 95816 EMPLOYEE COMPENSATION false ROBERT HICKEY SPOUSE OF BOARD MEMBER 192590 EMPLOYEE COMPENSATION false DANIEL ROSSI CHILD OF BOARD MEMBER 46093 EMPLOYEE COMPENSATION false SCHEDULE L, PART II LINDA H. MALKAS, PHD, WAS PROVIDED A MORTGAGE ASSISTANCE LOAN AS PART OF HER RECRUITMENT BY THE BECKMAN RESEARCH INSTITUTE. DR. MALKAS MAKES MONTHLY PRINCIPAL AND INTEREST PAYMENTS ON THIS LOAN AND IS CURRENT WITH ALL PAYMENTS. THE LOAN BEARS INTEREST AT 2.42 PERCENT PER ANNUM AND IS SECURED BY REAL PROPERTY IN THE STATE OF CALIFORNIA. THE NOTE IS DUE IN FULL FOR ANY REMAINING OUTSTANDING PRINCIPAL AND INTEREST THE EARLIER OF MAY 9, 2021 OR THE TERMINATION OF DR. MALKAS' EMPLOYMENT. FORM 990, PART III LINE 1 - CONTINUATION BECKMAN RESEARCH INSTITUTE'S MISSION IS TO SUPPORT INNOVATIVE AND CREATIVE RESEARCH AND TO EDUCATE FUTURE SCIENTISTS IN THE BIOLOGICAL SCIENCES. AT THE BECKMAN RESEARCH INSTITUTE, RESEARCH IS OF THE HIGHEST CALIBER AND DIRECTED TO AN UNDERSTANDING OF THE MOLECULES AND PROCESSES OF LIFE, INCLUDING THOSE PROCESSES IMPORTANT TO THE CAUSES, PREVENTION AND CURE OF HUMAN DISEASE. BECKMAN RESEARCH INSTITUTE IS PART OF AN INTEGRATED SYSTEM THAT COMBINES BENCH AND CLINICAL RESEARCH ACTIVITIES DIRECTLY WITH PATIENT CARE, IN BOTH AN IN-PATIENT AND OUT-PATIENT SETTING. THIS INTEGRATED SYSTEM KNOWN AS CITY OF HOPE COLLECTIVELY REFERS TO CITY OF HOPE, CITY OF HOPE NATIONAL MEDICAL CENTER, CITY OF HOPE MEDICAL FOUNDATION, BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, AND CITY OF HOPE AUXILIARIES. AS AN INNOVATIVE BIOMEDICAL RESEARCH, TREATMENT AND EDUCATIONAL INSTITUTION, WE ARE COMMITTED TO TRANSFORMING THE FUTURE OF HEALTH. EVERY DAY WE TURN SCIENCE INTO PRACTICAL BENEFIT. WE TURN HOPE INTO REALITY. WE ACCOMPLISH THIS THROUGH EXQUISITE CARE, INNOVATIVE RESEARCH, AND VITAL EDUCATION FOCUSED ON ELIMINATING CANCER, DIABETES AND OTHER LIFE-THREATENING DISEASES. CITY OF HOPE IS GUIDED BY A COMPASSIONATE, PATIENT-CENTERED PHILOSOPHY AND SUPPORTED BY A NATIONAL FOUNDATION OF PHILANTHROPY. FORM 990, PART III, LINE 4A - CONTINUATION RESEARCHERS AT BECKMAN RESEARCH INSTITUTE UNDERTAKE FUNDAMENTAL INVESTIGATIONS IN MOLECULAR GENETICS AND CELLULAR BIOLOGY, STUDYING BIOLOGICAL PROCESSES, CELL DIFFERENTIATION AND EARLY DEVELOPMENT, CELLULAR SIGNALING, RNA PROCESSING AND GENOMIC STRUCTURE. THEY HAVE ACHIEVED MAJOR ADVANCES IN RECOMBINANT DNA TECHNOLOGY, MONOCLONAL ANTIBODIES, GENE THERAPY, EPIGENETICS, SI-RNA TECHNOLOGY AND CANCER IMMUNOTHERAPEUTICS. A DEPARTMENT IN BECKMAN RESEARCH INSTITUTE IS DEDICATED TO UNDERSTANDING AND DEVELOPING TREATMENTS BASED ON CANCER'S INTERACTION WITH THE IMMUNE SYSTEM. OTHER RESEARCH HAS IDENTIFIED PROTEINS THAT MAY PLAY CRITICAL ROLES IN IMMUNE RESPONSE AND MAY LEAD TO NEW TREATMENT STRATEGIES. ANOTHER MAJOR EMPHASIS FOR THE BECKMAN RESEARCH INSTITUTE SCIENTISTS IS PERSONALIZED RESEARCH AND MEDICINE - ANALYZING PATIENTS' UNIQUE GENETIC PROFILES TO DEVELOP TAILORED THERAPIES FOR THEIR SPECIFIC DISEASE. ALL OF THIS RESEARCH IS UNIQUELY SUPPORTED BY ONSITE MANUFACTURING FACILITIES THAT CAN TEST AND PRODUCE QUANTITIES OF CELL-BASED, GENE-BASED AND MOLECULAR THERAPIES. THESE FACILITIES FURTHER SERVE AS RESOURCES TO MEDICAL AND SCIENTIFIC RESEARCH CENTERS NATIONWIDE. BECKMAN RESEARCH INSTITUTE SCIENTISTS SERVE AS FACULTY MEMBERS IN CITY OF HOPE'S IRELL & MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. THE GRADUATE SCHOOL'S MISSION IS TO TRAIN STUDENTS TO BE OUTSTANDING RESEARCH SCIENTISTS IN CHEMICAL, MOLECULAR AND CELLULAR BIOLOGY. THE SCHOOL IS ACCREDITED BY THE WESTERN ASSOCIATION OF SCHOOLS AND COLLEGES. GRADUATES OF THE PROGRAM, AWARDED A DOCTORATE OF PHILOSOPHY IN BIOLOGICAL SCIENCES, ARE EQUIPPED TO ADDRESS FUNDAMENTAL QUESTIONS IN LIFE SCIENCES AND BIOMEDICINE FOR CAREERS IN ACADEMIA, INDUSTRY AND GOVERNMENT. FORM 990, PART IV, QUESTION 13 AND SCHEDULE E THE BECKMAN RESEARCH INSTITUTE IS ENGAGED IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL AND SCIENTIFIC RESEARCH. BECKMAN RESEARCH INSTITUTE OPERATES A GRADUATE SCHOOL AND COMPLIES WITH REV. PROC. 75-50 EVEN THOUGH THE OPERATIONS OF THE GRADUATE SCHOOL IS LESS THAN 2% OF THE ORGANIZATION'S TOTAL EXPENSES. DUE TO LIMITATIONS IN THE 990 RETURN SOFTWARE APPLICATION, WE ARE UNABLE TO PROVIDE OUR RESPONSES TO THE SCHEDULE E, THEREFORE, THE FOLLOWING RESPONDS TO THE QUESTIONS IN THE SCHEDULE E SCHOOLS QUESTIONNAIRE: 1. DOES THE ORGANIZATION HAVE A RACIALLY NONDISCRIMINATORY POLICY TOWARD STUDENTS BY STATEMENT IN ITS CHARTER, BYLAWS, OTHER GOVERNING INSTRUMENT, OR IN A RESOLUTION OF ITS GOVERNING BODY? "YES" 2. DOES THE ORGANIZATION INCLUDE A STATEMENT OF ITS RACIALLY NONDISCRIMINATORY POLICY TOWARD STUDENTS IN ALL ITS BROCHURES, CATALOGUES, AND OTHER WRITTEN COMMUNICATIONS WITH THE PUBLIC DEALING WITH STUDENT ADMISSIONS, PROGRAMS, AND SCHOLARSHIPS? "YES" 3. HAS THE ORGANIZATION PUBLICIZED ITS RACIALLY NONDISCRIMINATORY POLICY THROUGH NEWSPAPER OR BROADCAST MEDIA DURING THE PERIOD OF SOLICITATION FOR STUDENTS, OR DURING THE REGISTRATION PERIOD IF IT HAS NO SOLICITATION PROGRAM, IN A WAY THAT MAKES THE POLICY KNOWN TO ALL PARTS OF THE GENERAL COMMUNITY IT SERVES? IF YES, PLEASE DESCRIBE, IF NO, PLEASE EXPLAIN. "NO." THE GRADUATE SCHOOL CUSTOMARILY DRAWS A SUBSTANTIAL PERCENTAGE OF ITS STUDENTS FROM LARGE GEOGRAPHIC SECTIONS OF THE UNITED STATES AND INTERNATIONALLY, AND FOLLOWS A RACIALLY NONDISCRIMINATORY POLICY AS DEMONSTRATED BY ITS CURRENT ENROLLMENT OF STUDENTS OF RACIAL MINORITY GROUPS IN MEANINGFUL NUMBERS. ACCORDINGLY, THE GRADUATE SCHOOL SATISFIES THE PUBLICITY REQUIREMENTS OF SECTION 4.03 BY COMPLYING WITH SECTION 4.02 IN THAT IT INCLUDES A STATEMENT OF ITS RACIALLY NONDISCRIMINATORY POLICY AS TO STUDENTS IN ITS CATALOGUES AND ON THE ORGANIZATION'S WEBSITE. 4. DOES THE ORGANIZATION MAINTAIN THE FOLLOWING: 4A. RECORDS INDICATING THE RACIAL COMPOSITION OF THE STUDENT BODY, FACULTY, AND ADMINISTRATIVE STAFF? "YES" 4B. RECORDS DOCUMENTING THAT SCHOLARSHIPS AND OTHER FINANCIAL ASSISTANCE ARE AWARDED ON A RACIALLY NONDISCRIMINATORY BASIS? "YES" 4C. COPIES OF ALL CATALOGUES, BROCHURES, ANNOUNCEMENTS, AND OTHER WRITTEN COMMUNICATIONS TO THE PUBLIC DEALING WITH STUDENT ADMISSIONS, PROGRAMS, AND SCHOLARSHIPS? "YES" 4D. COPIES OF ALL MATERIAL USED BY THE ORGANIZATION OR ON ITS BEHALF TO SOLICIT CONTRIBUTIONS? "YES" 5. DOES THE ORGANIZATION DISCRIMINATE BY RACE IN ANY WAY WITH RESPECT TO: 5A. STUDENT'S RIGHTS OR PRIVILEGES? "NO" 5B. ADMISSIONS POLICIES? "NO" 5C. EMPLOYMENT OF FACULTY OR ADMINISTRATIVE STAFF? "NO" 5D. SCHOLARSHIPS OR OTHER FINANCIAL ASSISTANCE? "NO" 5E. EDUCATIONAL POLICIES? "NO" 5F. USE OF FACILITIES? "NO" 5G. ATHLETIC PROGRAMS? "NO" 5H. OTHER EXTRACURRICULAR ACTIVITIES? "NO" 6A. DOES THE ORGANIZATION RECEIVE ANY FINANCIAL AID OR ASSISTANCE FROM A GOVERNMENTAL AGENCY? "NO" 6B. HAS THE ORGANIZATION'S RIGHT TO SUCH AID EVER BEEN REVOKED OR SUSPENDED? "NO" 7. DOES THE ORGANIZATION CERTIFY THAT IT HAS COMPLIED WITH THE APPLICABLE REQUIREMENTS OF SECTIONS 4.01 THROUGH 4.05 OF REV. PROC. 75-50, 1975-2C.B. 587, COVERING RACIAL NONDISCRIMINATION? "YES" FORM 990, PART VI, SECTION A, LINE 6 AND 7A THE SOLE CORPORATE MEMBER, CITY OF HOPE (95-3435919), ELECTS THE BOARD THE MEMBERS OF DIRECTORS TO BECKMAN RESEARCH INSTITUTE. FORM 990, PART VI, SECTION A, LINE 7B CERTAIN ACTIONS MAY NOT BE UNDERTAKEN WITHOUT THE PRIOR WRITTEN APPROVAL OF THE SOLE CORPORATE MEMBER, CITY OF HOPE, AS SPECIFIED IN THE GOVERNING DOCUMENTS OF BECKMAN RESEARCH INSTITUTE, INCLUDING: BORROW MONEY IN THE NAME OF BECKMAN RESEARCH INSTITUTE OR UTILIZING PROPERTY OWNED BY BECKMAN RESEARCH INSTITUTE AS SECURITY FOR SUCH LOANS; ASSIGN, TRANSFER, PLEDGE, COMPROMISE OR RELEASE ANY OF THE CLAIMS OR DEBTS TO BECKMAN RESEARCH INSTITUTE EXCEPT ON PAYMENT IN FULL, OR ARBITRATE OR CONSENT TO THE ARBITRATION OF ANY DISPUTE OR CONTROVERSY OF BECKMAN RESEARCH INSTITUTE; MAKE, EXECUTE OR DELIVER ANY ASSIGNMENT FOR THE BENEFIT OF CREDITORS, OR ANY BOND, CONFESSION OF JUDGMENT, CHATTEL MORTGAGE, SECURITY AGREEMENT, DEED, GUARANTY, INDEMNITY BOND, SURETY BOND, OR CONTRACT TO SELL OR BILL OF SALE OF THE PROPERTY OF BECKMAN RESEARCH INSTITUTE; ACQUIRE, PURCHASE, DEVELOP, IMPROVE, SELL, LEASE, OR MORTGAGE ANY CORPORATE REAL ESTATE OR ANY INTEREST THEREIN OR ENTER INTO ANY CONTRACT FOR ANY SUCH PURPOSES; OR MAKE ANY LOAN, INVESTMENT, TRANSFER OR DISPOSITION OF ANY ASSETS OF BECKMAN RESEARCH INSTITUTE OR ENTER INTO ANY CONTRACT OR INCUR ANY LIABILITIES ON BEHALF OF BECKMAN RESEARCH INSTITUTE OTHER THAN FOR FAIR CONSIDERATION AND IN THE ORDINARY COURSE OF BUSINESS RELATING TO ITS NORMAL DAILY OPERATION; OR ESTABLISH CAPITAL AND OPERATING BUDGETS OR ADOPT MATERIAL CHANGES THERETO; OR ANY ACTION THAT COULD REASONABLY BE EXPECTED TO HAVE A MATERIAL ADVERSE EFFECT ON THE 501(C)(3) STATUS OF TAX-EXEMPT BONDS OF CITY OF HOPE AND AFFILIATES. THE FOLLOWING REQUIRE GOVERNING BODY APPROVAL (AS WELL AS THE APPROVAL OF THE SOLE CORPORATE MEMBER): THE ADOPTION OF, OR MATERIAL CHANGE IN, THE MISSION OF BECKMAN RESEARCH INSTITUTE; SALE OR DISPOSITION OF ALL OR SUBSTANTIALLY ALL ASSETS; MERGER AND ITS PRINCIPAL TERMS (AND ANY AMENDMENT TO THOSE TERMS); DISSOLUTION OF THE CORPORATION; ADOPTION OF OPERATING AND CAPITAL BUDGETS; ACQUISITIONS AND CAPITAL EXPENDITURES MEETING A CERTAIN FINANCIAL THRESHOLD; BORROWINGS, GUARANTIES, LOANS, AND BOND ISSUANCE MEETING A CERTAIN FINANCIAL THRESHOLD; CREATION OF A NEW (OR ACQUISITION OF A CONTROLLING INTEREST IN AN EXISTING) CORPORATION, PARTNERSHIP OR LIMITED LIABILITY COMPANY; AND ADOPTION OF OR AMENDMENTS TO INDIVIDUAL CORPORATE INVESTMENT GUIDELINES. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FORM 990 IS REVIEWED BY THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD OF DIRECTORS OF CITY OF HOPE, WHICH ASSISTS THE BECKMAN RESEARCH INSTITUTE'S BOARD IN FULFILLING ITS RESPONSIBILITIES REGARDING FINANCIAL, ACCOUNTING, AND CORPORATE COMPLIANCE MATTERS OF BECKMAN RESEARCH INSTITUTE. CITY OF HOPE'S AUDIT AND COMPLIANCE COMMITTEE, WHICH ACTS PURSUANT TO A DELEGATION OF AUTHORITY FROM THE CITY OF HOPE, ALSO SERVES AS THE AUDIT AND COMPLIANCE COMMITTEE OF BECKMAN RESEARCH INSTITUTE. ADDITIONALLY, THE PREPARATION OF THE FORM 990 IS DONE INTERNALLY AND IS REVIEWED THOROUGHLY WITH INTERNAL LEADERSHIP AND EXTERNAL PARTICIPANTS, INCLUDING EY AND RETAINED OUTSIDE TAX COUNSEL. PRIOR TO FILING, THE BECKMAN RESEARCH INSTITUTE FORM 990 IS MADE AVAILABLE TO VOTING MEMBERS OF THE CITY OF HOPE BOARD OF DIRECTORS FOR REVIEW ELECTRONICALLY. FORM 990, PART VI, SECTION B, LINE 12C ALL EMPLOYEES OF CITY OF HOPE AND AFFILIATES, MEMBERS OF THE BOARDS OF DIRECTORS, BOARD COMMITTEE MEMBERS AND RESEARCH TEAM MEMBERS ARE COVERED BY CITY OF HOPE'S APPLICABLE CONFLICT OF INTEREST POLICIES. DETERMINATIONS AS TO WHETHER A CONFLICT OF INTEREST EXISTS AND REVIEW OF SUCH CONFLICT DISCLOSURES ARE MADE BY THE CHIEF RISK OFFICER, GENERAL COUNSEL AND, AS APPLICABLE, THE CHAIR OF THE BOARD OR BOARD OF DIRECTORS OR THE CONFLICT OF INTEREST AND COMMITMENT COMMITTEE, BASED UPON THE CATEGORY OF PERSON MAKING THE DISCLOSURE. RESTRICTIONS IMPOSED ON PERSONS WITH A CONFLICT VARY, BASED UPON THE FACTS AND MAY INCLUDE: PROHIBITION FROM PARTICIPATING IN A GOVERNING BODY'S DELIBERATIONS AND VOTING ON A GIVEN TRANSACTION OR SET OF TRANSACTIONS; RECUSAL FROM THE DECISION-MAKING PROCESS RELATING TO BUSINESS TRANSACTIONS (E.G., PURCHASING DECISIONS); PROHIBITION FROM PARTICIPATING AS A PRINCIPAL INVESTIGATOR IN RESEARCH; AND DISCLOSURE OF FINANCIAL INTEREST IN RESEARCH STUDY INFORMED CONSENT FORMS AND PUBLICATIONS. MONITORING TRANSACTIONS FOR CONFLICTS OF INTEREST IS DONE THROUGH ANNUAL REQUIRED DISCLOSURES AND UPDATES BY PERSONS COVERED BY THE ORGANIZATION'S CONFLICT OF INTEREST POLICIES AND A CONCURRENT REVIEW OF SUCH DISCLOSURES AGAINST TRANSACTIONS. CITY OF HOPE POLICY PROVIDES FOR DISCIPLINARY ACTION AGAINST PERSONS COVERED BY THE CONFLICT OF INTEREST POLICIES WHO DO NOT COMPLY WITH POLICY REQUIREMENTS. SCHEDULE O, FORM 990, PART VI, SECTION B, LINES 15A AND 15B THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE BOARD OF DIRECTORS ("COMMITTEE"), PURSUANT TO A DELEGATION OF AUTHORITY FROM THE CITY OF HOPE BOARD OF DIRECTORS, IS RESPONSIBLE FOR SETTING THE COMPENSATION OF THE CEO AND CERTAIN OTHER SENIOR EXECUTIVES. THE COMMITTE ALSO SERVES AS THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTE OF THE BECKMAN RESEARCH INSTITUTE. THE DIRECTORS ON THIS COMMITTEE ARE INDEPENDENT AND ADHERE TO A STRICT CONFLICT OF INTEREST POLICY. DELIBERATION AND DECISION MAKING ARE SUBSTANTIATED IN THE MINUTES OF THE COMMITTEE'S MEETINGS. THE MINUTES ARE REVIEWED AND APPROVED AT THE NEXT MEETING OF THE COMMITTEE. AS PART OF THE DELIBERATION PROCESS, THE COMMITTEE RECEIVES ADVICE FROM AN INDEPENDENT, THIRD-PARTY COMPENSATION CONSULTANT WITH RESPECT TO EXECUTIVE COMPENSATION, INCLUDING REVIEW OF COMPARABLE AND OTHER BENCHMARK DATA, CURRENT COMPENSATION PHILOSOPHY, STRUCTURE, AND ADMINISTRATION OF THE EXECUTIVE CASH COMPENSATION PROGRAMS AT CITY OF HOPE AND AFFILIATES. THE COMMITTEE CARRIES OUT THE BOARD OF DIRECTORS' OVERALL RESPONSIBILITIES RELATING TO EXECUTIVE COMPENSATION. THE EXECUTIVE COMPENSATION PHILOSOPHY IS DESIGNED TO ATTRACT AND RETAIN THE CALIBER OF EXECUTIVE LEADERSHIP REQUIRED TO ENABLE CITY OF HOPE TO ACHIEVE THE HIGHEST LEVELS OF COMMUNITY BENEFIT, IMPACT TO CLINICAL CARE, QUALITY RESEARCH AND EFFICIENT PHILANTHROPIC DEVELOPMENT. THE COMMITTEE TARGETS THE 50TH PERCENTILE OF BASE SALARY AND THE 75TH PERCENTILE OF TOTAL CASH COMPENSATION OF THE MARKET IN WHICH BECKMAN RESEARCH INSTITUTE COMPETES FOR EXECUTIVES. A SUBSTANTIAL PORTION OF EXECUTIVE COMPENSATION IS LINKED DIRECTLY TO PERFORMANCE GOALS APPROVED IN ADVANCE BY THE COMMITTEE. THESE GOALS ARE TIED TO THE PERFORMANCE OF CITY OF HOPE AND AFFILIATES, INCLUDING THE ATTAINMENT OF SPECIFIC BUSINESS OBJECTIVES FOR STRATEGIC AND FINANCIAL PERFORMANCE AS WELL AS NON-FINANCIAL MEASURES SUCH AS PATIENT SATISFACTION AND QUALITY OF PATIENT CARE. AS A CONSEQUENCE, PERFORMANCE COMPENSATION MAY VARY FROM YEAR TO YEAR. THE COMMITTEE CONDUCTS ANNUAL COMPENSATION REVIEWS FOR EXECUTIVES AND CERTAIN KEY EMPLOYEES AND THIS WAS LAST COMPLETED ON DECEMBER 18, 2015. THE COMPENSATION PROGRAMS AND RANGES FOR ALL OFFICERS AND KEY EMPLOYEES LISTED ON FORM 990, PART VII AT THE SVP OR EQUIVALENT LEVEL AND ABOVE ARE REVIEWED BY THIS COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 BECKMAN RESEARCH INSTITUTE'S ARTICLES OF INCORPORATION ARE AVAILABLE TO THE PUBLIC FROM THE SECRETARY OF STATE. CITY OF HOPE AND AFFILIATES' AUDITED FINANCIAL STATEMENTS ARE AVAILABLE ON THE CITY OF HOPE WEBSITE, AND ITS CONFLICT OF INTEREST POLICIES ARE AVAILABLE BY WRITTEN REQUEST MADE TO THE CONFLICT OF INTEREST MANAGER. BECKMAN RESEARCH INSTITUTE'S BYLAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. FORM 990, PART VII, COLUMN (B) FULL TIME EXEMPT EMPLOYEES GENERALLY WORK IN EXCESS OF 40 HOURS PER WEEK, WHICH HAS BEEN REFLECTED IN PART VII BY AN ESTIMATE OF 60 HOURS PER WEEK. THE MEMBERS OF THE BOARD OF DIRECTORS ARE NOT COMPENSATED FOR SERVING ON THE BOARD. THE HOURS WORKED FOR EACH DIRECTOR IS AN ESTIMATE OF THE TIME SPENT PREPARING FOR AND ATTENDING MEETINGS OF THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS HELD THREE REGULARLY SCHEDULED MEETINGS DURING FISCAL YEAR 2015. THE AUDIT AND COMPLIANCE COMMITTEE HELD 5 REGULARLY SCHEDULED MEETINGS IN FISCAL YEAR 2015. MOST OF THE CITY OF HOPE OFFICERS AND KEY EMPLOYEES, AS WELL AS A FEW OF ITS HIGHEST COMPENSATED EMPLOYEES, PROVIDE SERVICES TO MORE THAN ONE CITY OF HOPE ENTITY, AND MANY OF THEM PROVIDE SERVICES TO ALL OF THE ENTITIES. FOR A NUMBER OF THESE CONCURRENTLY-EMPLOYED INDIVIDUALS, THE ENTITIES HAVE DESIGNATED THE MEDICAL CENTER AS THE "COMMON PAYMASTER," AS IS DEFINED IN SECTION 3121(S) OF THE INTERNAL REVENUE CODE. CITY OF HOPE REPORTS THESE CONCURRENT EMPLOYEES' TIME, EFFORT AND COMPENSATION ON THE INFORMATION RETURNS OF THE CITY OF HOPE ENTITIES BASED ON THE EMPLOYEES ESTIMATES OF THEIR TIME SPENT IN AND FOR EACH SUCH ENTITY. AS "COMMON PAYMASTER," THE MEDICAL CENTER ISSUES EACH OF THESE EMPLOYEES A SINGLE, COMBINED PAYCHECK AND ONE FORM W-2. FORM 990, PART XI,LINE 9 LOSS ON CHANGE IN FAIR VALUE OF INTEREST RATE SWAP AGREEMENT (2,181,314) CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 FUNDRAISING CA 501(C)3 7 NA false CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 HOSPITAL CA 501(C)3 3 CITY OF HOPE true City of Hope Medical Foundation 1500 E Duarte Road Duarte CA 91010 274803222 Healthcare CA 501(C)3 3 City of Hope true false false true false false false false false false false false true true false true true true false false CITY OF HOPE NATIONAL MEDICAL CENTER P 34296517 FMV CITY OF HOPE NATIONAL MEDICAL CENTER Q 14545618 FMV CITY OF HOPE NATIONAL MEDICAL CENTER O 16336914 FMV CITY OF HOPE NATIONAL MEDICAL CENTER M 24499937 FMV CITY OF HOPE NATIONAL MEDICAL CENTER L 711589 FMV